Motley Fool Australia

Why the CLINUVEL (ASX:CUV) share price is shooting higher

asx share price growth represented by rocket flying up increasing bar chart.
Image source: Getty Images

The CLINUVEL Pharmaceuticals Limited (ASX: CUV) share price has been a very strong performer on Thursday.

In morning trade the biopharmaceutical company’s shares are up 5.5% to $20.80.

Why is the CLINUVEL share price storming higher?

Investors have been buying CLINUVEL’s shares after it announced plans to expand its SCENESSE drug (afamelanotide 16mg) to treat the disease xeroderma pigmentosum (XP).

XP is rare genetic disorder affecting 1 in 1 million in the United States and Europe. Sufferers have the most extreme deficiencies in their DNA repair processes, leading to a 10,000-fold increase in their risk of skin cancer. There is no known cure for XP at present.

Having commercialised SCENESSE in Europe and the USA for the rare genetic disorder Erythropoietic Protoporphyria (EPP), CLINUVEL is now aiming to confirm how intervention with the drug enhances elimination of photoproducts and regeneration of DNA.

CLINUVEL’s Chief Scientific Officer, Dr Dennis Wright, commented “In SCENESSE we have a hormone acting on various organs and receptors, but most of all known to protect human DNA. Our task is to confirm how DNA regeneration occurs within genetically affected patients and healthy subjects.”

“Tragically, XP provides an extreme model of what happens to our skin if UV-induced damage is left unrepaired. From a young age, XP patients are incapable of responding to DNA damage caused by UV exposure and experience disfiguring and aggressive skin cancers.”

“After two decades of clinical research, I’m delighted that our team can now focus on the XP patients who are severely affected by UV radiation leaving them a short life expectancy. We will facilitate treatment for the first patient in the next few weeks,” Dr Wright said.

The company advised that the first clinical results from the DNA repair program are expected to be reported in 2021.

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

*Returns as of 15/2/2021

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Related Articles…

Latest posts by James Mickleboro (see all)